A phase 2, open label trial to evaluate safety, tolerability and efficacy of guadecitabine (SGI-110) in patients with T-cell lymphoma
Latest Information Update: 22 Jun 2022
At a glance
- Drugs Guadecitabine (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms STELLAR
- 01 Jun 2022 Results assessing integrated clinical and genomic evaluation of guadecitabine in peripheral T-cell lymphoma published in the Leukemia
- 17 Dec 2018 Status changed from not yet recruiting to recruiting.
- 16 Jan 2018 New trial record